In contrast, we did not find evidence of potential adverse effects for potentially novel targets, such as SLC12A5 (depression, P = 7.13 × 10−10), NMB (bipolar disorder, P = 1.70 × 10−6) and PRSS36 (Alzheimer’s disease, P = 7.30 × 10−8), deeming them potentially promising and worthwhile druggable loci. This evidence concerns the gene SLC12A5 and bipolar disorder.